National Pharmacy Health & Leadership Alliance Verify a MemberMember Login

What changed today in Metabolic: 6 trial updates, 1 new study

Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.

The signal

NPHLA tracked 7 new official records on this desk today: 6 trial updates, 1 new study.

Why this matters

GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.

What changed

  1. New trial registered: CKM-T2D (Clinical Predictors and Therapeutic Gaps in CKM Syndrome Among Adults With Type 2 Diabetes)[1]
  2. New trial registered: A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment…[2]
  3. New trial registered: SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight[3]
  4. Trial status changed to “Active, not recruiting”: ATTAIN-OA PAIN (A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee)[4]
  5. New trial registered: Hypothalamic GLP-1 Response in Healthy Weight and Obesity[5]
  6. New trial registered: Effects of Pistachios on Postprandial Metabolic Responses in Adults With Overweight or Obesity[6]
  7. New research in Advances in clinical and experimental medicine : official organ Wroclaw Medical University: “Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics”.[7]
  8. Also reported by American Med Spa Association: “Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds”.[8]
  9. Also reported by MedPage Today: “Retatrutide Delivers Substantial Weight Loss in Type 2 Diabetes”.[9]
  10. Also reported by Drug Topics: “Data Links GLP-1 With Fewer Asthma Attacks, Lower Psychiatric Risk”.[10]

Who this affects

  • Weight-management clinics
  • Med spas
  • Pharmacists
  • Prescribers
  • Medical directors
  • Practice owners & operators

What to watch next

No new verified deadlines in today’s records. See Deadline Watch for upcoming dates.

NPHLA takeaway

These are factual summaries of official records with no interpretation. Open the primary documents for full details; NPHLA editors add analysis where developments warrant it.

Source file

  1. [1]
  2. [2]
  3. [3]
  4. [4]
  5. [5]
    New trial registered: Hypothalamic GLP-1 Response in Healthy Weight and Obesity (opens the source in a new tab)

    Primary sourceClinicalTrials.gov (U.S. National Library of Medicine)

  6. [6]
  7. [7]
    Diet and nutrition in obesity treated with incretin-based therapies: A scientific statement of the Polish Society of Dietetics (opens the source in a new tab)

    Peer reviewedAdvances in clinical and experimental medicine : official organ Wroclaw Medical University

  8. [8]
    Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds (opens the source in a new tab)

    News reportingAmerican Med Spa AssociationIndustry coverage — headline and link only

  9. [9]
    Retatrutide Delivers Substantial Weight Loss in Type 2 Diabetes (opens the source in a new tab)

    News reportingMedPage TodayIndustry coverage — headline and link only

  10. [10]
    Data Links GLP-1 With Fewer Asthma Attacks, Lower Psychiatric Risk (opens the source in a new tab)

    News reportingDrug TopicsIndustry coverage — headline and link only

Compiled automatically from primary official sources and peer-reviewed literature. Each line is a factual summary of a public record, linked to it — no interpretation is added. NPHLA links to sources and does not republish their text. Professional information only — not medical, legal or regulatory advice for any individual situation. Our standards.

Update timeline

  1. First published.
  2. Added 6 new official records.